Proactive Investors - Run By Investors For Investors

Namaste's agreed-upon medical cannabis vendor Agraflora provides additional information on supply deal

The supplier is meeting a request from the Investment Industry Regulatory Organization of Canada
A marijuana plant
The cannabis deal is subject to approval of Agraflora’s cultivation and sales licenses

Namaste Technologies Inc’s (CVE:N) (OTCMKTS:NXTTF) agreed-upon medical cannabis vendor Agraflora Organics International Inc (CSE AGRA) (OTCMKTS:PUFXF) said it provided additional information on its supply agreement at the request of the Investment Industry Regulatory Organization of Canada.

Under the deal announced Thursday, Toronto-based Namaste’s Cannmart unit has the right of first refusal to purchase up to 10% of the total annual production from Agraflora's Delta, British Columbia, greenhouse complex. That represents 25 million grams, at a price of C$4 per gram, or as much as C$100 million.

READ: Namaste unit may buy up to C$100M of medical cannabis from Agraflora Organics annually

The deal is subject to approval of Agraflora’s cultivation and sales licenses by Health Canada.

When the 2.2-million-square-foot Delta greenhouse complex is fully operational in 2021, it is projected to have an annual capacity of 250 million grams of high-quality cannabis.

Shares of Namaste traded at C$1.23 in Thursday’s Canadian trading. They slipped US$0.04 to US$0.93 on the OTC Markets. Agraflora traded at C$0.22 in Canada and gained US$0.03 to US$0.16 on the OTC Markets.

Contact Dennis Fitzgerald at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use